Zephyr AI Raises $111M Series A Funding to Pioneer Precision Medicine with Explainable AI Solutions
Zephyr AI is on a mission to harness the power of artificial intelligence for precision medicine positions the company to revolutionize patient care and treatment outcomes in critical areas such as oncology and cardiometabolic disease.
Company Name: Zephyr AI
Location: McLean, VA
Sector: Healthcare Technology
Funding Details: Closed $111M in Series A funding with backers including Revolution Growth, Eli Lilly & Company, Jeff Skoll, and EPIQ Capital Group, among others.
Purpose of Investment: To enhance analytical speed, fortify training and validation datasets, expand scientific and commercial teams, and expedite the delivery of insights to the market.
Leadership: Co-Founders Grant Verstandig (Executive Chairman) and Jeff Sherman (Interim CEO and Chief Technology Officer)
Product: Zephyr AI is advancing precision medicine through explainable AI solutions, focusing on data federation tools and machine learning algorithms in oncology and cardiometabolic disease. Its comprehensive healthcare dataset combined with AI algorithms aims to support patients, providers, and ongoing research.
About Company: Zephyr AI stands at the forefront of healthcare innovation. Its mission to harness the power of artificial intelligence for precision medicine positions the company to revolutionize patient care and treatment outcomes in critical areas such as oncology and cardiometabolic disease.
